Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Richard M Elledge"'
Autor:
Richard M. Elledge, Courtney Thomas, Jonathan Gelfond, Sarah Hackman, Kate Lathrop, Virginia G. Kaklamani, Alia Nazarullah, Andrew Brenner, Rong Li, Marisa Rodriguez
Publikováno v:
Cancer Research. 81:PS5-31
Introduction: Patients with TNBC breast cancer have inferior treatment outcomes compared to other breast cancer subtypes and targeted therapies are lacking. S-equol is a novel oral Estrogen Receptor (ER) Beta agonist with preclinical data showing sup
Autor:
Nameer B. Kirma, Tim H M Huang, Virginia G. Kaklamani, Chia-Nung Hung, Kate Lathrop, Chih-Wei Chou, Ya-Ting Hsu, Chun Liang Chen, Meizhen Chen, Chun-Lin Lin, Kohzoh Mitsuya, Richard M. Elledge, Ching-Hung Lin, Meena Kusi, Chiou-Miin Wang, Xi Tan
Publikováno v:
BMC Medical Genomics
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-18 (2020)
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-18 (2020)
Background Chromothripsis is an event of genomic instability leading to complex chromosomal alterations in cancer. Frequent long-range chromatin interactions between transcription factors (TFs) and targets may promote extensive translocations and cop
Autor:
Richard M. Elledge, Donald A. Richards, Sharon Wilks, Peter Kabos, Virginia G. Kaklamani, H Jiang, D Wang, Aditya Bardia, A O'Neill, Wael A. Harb, F Garner
Publikováno v:
Cancer Research. 78:PD5-08
This abstract was not presented at the symposium.
Autor:
Long Cheng, Ratna K. Vadlamudi, Harshita Gupta, Degeng Wang, Kshama Gupta, Kate Lathrop, Huai-Chin Chiang, Rong Li, Stanton F. McHardy, Bin Yuan, Gangadhara R. Sareddy, Richard M Elledge, Yanfen Hu, Tyler J. Curiel, Qinong Ye, Pei Wang
Publikováno v:
Oncotarget
Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dictates
Autor:
Richard M Elledge, Behyar Zoghi
Publikováno v:
The Breast Journal. 22:218-223
Leptomeningeal disease is an uncommon complication of estrogen receptor positive breast cancer. While there is little consensus on the standard of care, recommendations from current clinical practice guidelines are to treat with intrathecal chemother
Autor:
Marisa Rodriguez, Kate Ida Lathrop, Virginia G. Kaklamani, Alia Nazarullah, Andrew Brenner, Jonathan Gelfond, Sarah Hackman, Courtney Thomas, Richard M. Elledge, Rong Li
Publikováno v:
Journal of Clinical Oncology. 38:560-560
560 Background: Patients with TNBC breast cancer have inferior treatment outcomes compared to other breast cancer subtypes and targeted therapies are lacking. S-equol is a novel oral Estrogen Receptor (ER) Beta agonist with preclinical data showing s
Autor:
Bushra Rahman, Meghan Morrison Joly, Courtney McKernan, Michelle M. Williams, Rebecca S. Cook, Violeta Sanchez, Monica V. Estrada, Linus Lee, Richard M. Elledge, David L. Elion, Donna J. Hicks, Thomas A. Werfel, Suleiman Massarweh, Craig L. Duvall
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 9, Iss 2, Pp 1-14 (2018)
Cell Death and Disease, Vol 9, Iss 2, Pp 1-14 (2018)
Estrogen receptor-α positive (ERα+) breast cancer accounts for approximately 70–80% of the nearly 25,0000 new cases of breast cancer diagnosed in the US each year. Endocrine-targeted therapies (those that block ERα activity) serve as the first l
Autor:
Richard M Elledge, Zhi-Min Yuan, Ronan T. Swords, Tony Yuen Eng, Carol A. Jenkins, Richard L. Crownover, Joel E. Michalek, Anand B. Karnad, Chul S. Ha, Brad H. Pollock, Kevin R. Kelly, Suthakar Ganapathy, Gregory P. Swanson, Su Hang, Martin Goros, Athanassios Argiris
Publikováno v:
Molecular Oncology. 10:148-156
p53 activation is a primary mechanism underlying pathological responses to DNA damaging agents such as chemotherapy and radiotherapy. Our recent animal studies showed that low dose arsenic (LDA)-induced transient p53 inhibition selectively protected
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2015, Iss 9, Pp 25-29 (2015)
Breast Cancer : Basic and Clinical Research
Breast Cancer : Basic and Clinical Research
Women carrying BRCA1 and BRCA2 mutations have significantly elevated risk of developing breast and ovarian cancers. BRCA1-associated breast cancer likely originates from progenitors of the luminal epithelial lineage. Recent studies indicate that radi
Autor:
Frédéric Chédin, Constantine Theoharis, Beth N. Peshkin, Meeghan A. Lautner, Victor X. Jin, Boyce B Oliver, Anna Petit, Huai-Chin Chiang, Xiaowen Zhang, Tyler J. Curiel, Yao Wang, Elizabeth Poggi, Rong Li, Sreejith J. Nair, Miguel Angel Pujana, Claudine Isaacs, Joan Brunet, Krysta Chaldekas, Richard M Elledge, Ismail Jatoi, Yanfen Hu, Chi Zhang, Joel E. Michalek, Oscar Ochoa, Xiayan Zhao, Teresa Soler, Francesca Mateo, Howard T. Wang, Lu-Zhe Sun, Sabrina Smith
Publikováno v:
Nature communications, vol 8, iss 1
Nature Communications
Dipòsit Digital de la UB
Universidad de Barcelona
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
Recercat. Dipósit de la Recerca de Catalunya
instname
Nature Communications
Dipòsit Digital de la UB
Universidad de Barcelona
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
Recercat. Dipósit de la Recerca de Catalunya
instname
Most BRCA1-associated breast tumours are basal-like yet originate from luminal progenitors. BRCA1 is best known for its functions in double-strand break repair and resolution of DNA replication stress. However, it is unclear whether loss of these ubi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebfb2d661f14aef7e1fd7059dfd72dcd
https://escholarship.org/uc/item/64t102b5
https://escholarship.org/uc/item/64t102b5